Absorbable Hydrogel Spacer
Customize your policy alerts
Sign up for Geisinger Health Plan Policy MP320 alerts
Get alerted when Policy MP320 changes without checking for updates manually.
Monitor payer policy activity
Policy governing coverage of FDA‑approved absorbable rectal hydrogel spacers (e.g., SpaceOAR) to reduce rectal and urinary toxicity for men undergoing radiotherapy for prostate cancer; applies to Geisinger Health Plan lines of business per member benefit documents.
No material clinical or coverage changes in this revision.
Coverage Criteria for Absorbable Hydrogel Spacer
Indications for Coverage
Covered when ALL of the following are met
Explicitly limited to men with prostate cancer receiving radiotherapy per policy indications.
Use of absorbable hydrogel spacers outside the indications listed in this policy is considered unproven and is therefore NOT COVERED. There is insufficient evidence in the peer‑reviewed literature to establish effectiveness of these spacers for indications other than those specified in this policy.
Coverage for experimental or investigational treatments, services, and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to items or services that are excluded by the member's benefit document; see MP015 Experimental, Investigational or Unproven Services for additional information.
Unproven services provided outside of an approved clinical trial are specifically excluded (not covered) under the member's certificate with Geisinger Health Plan. Prior authorization and pre‑certification requirements may still apply per the member’s contract and the Geisinger provider clinical policies web page.
Associated Procedure and Billing Codes
| 55874 | Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed |
Provider Actions, Prior Authorization, and Billing Notes
Prior authorization & coding note — CPT 55874; verify member benefits
Procedure code 55874 (Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed) is listed in the coding section; coverage and reimbursement are determined by the member-specific benefit plan document and any applicable laws or Medicare rules.
- 55874 — Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed
- Inclusion of a code does not guarantee coverage or reimbursement; verify member benefits.
Prior authorization may be required — consult member contract and Geisinger resources
Prior authorization and/or pre‑certification may be required for this service; providers must consult the member's contract and the Geisinger provider clinical policies site for specific prior authorization requirements.
- Check the member-specific contract/benefit document for precertification lists.
- Prior authorization requirements are posted at the Geisinger provider clinical policies web page.
Step therapy — none specified in policy
No step therapy requirements are specified in this policy; applicability of any utilization management requirements depends on the member benefit document and, for Medicare members, applicable LCDs/NCDs.
- Verify any additional requirements in the member's benefit document and applicable Medicare LCD/NCD.
Verify eligibility and contract-specific benefits; LOB documents supersede policy
Coverage is limited to the policy indication and to members meeting eligibility and contract‑specific benefits; line‑of‑business benefit documents supersede this policy and Medicare LCDs/NCDs will supersede the policy for Medicare members.
- Verify member eligibility and contract-specific benefits, limitations, and exclusions before ordering.
- For Medicare members, confirm applicable LCD/NCDs.
Coverage subject to eligibility and contract limitations
Coverage is subject to member eligibility and contract-specific benefits, limitations, and exclusions; benefits found in line‑of‑business documents supersede this policy.
- Confirm benefits, limitations, or exclusions in the member's contract prior to scheduling the procedure.
Prior authorization and precertification sources — where to find requirements
Precertification lists and prior authorization requirements may apply and are located in the member's contract-specific benefit document and on the Geisinger provider clinical policies web page.
- Precertification lists: member's contract-specific benefit document.
- Prior authorization requirements: https://www.geisinger.org/health-plan/providers/ghp-clinical-policies
Requests for hydrogel spacer use outside listed indication — considered unproven/NOT COVERED
Requests to use absorbable hydrogel spacers for indications outside those listed in this policy (i.e., other than men with prostate cancer undergoing radiotherapy) are considered unproven and are NOT COVERED; such requests may be denied.
- Use outside listed indications is considered unproven due to insufficient evidence in peer‑reviewed literature.
- Do not expect approval for non‑listed indications without supporting evidence or an approved clinical trial.
Exclusion triggers — experimental/investigational or unproven services excluded
Coverage for experimental or investigational treatments, services, and procedures — and unproven services outside an approved clinical trial — are specifically excluded under the member's certificate and may trigger denials.
- This policy does not expand coverage to services/items specifically excluded in the member's certificate.
- See MP015 for additional information on experimental/investigational/unproven services.
Clinical Background
Absorbable hydrogel spacers are an injectable polyethylene glycol‑based hydrogel placed between the prostate and rectum under ultrasound guidance to increase separation and reduce rectal radiation dose during prostate radiotherapy. The polymer typically solidifies within seconds, remains in place for approximately 3 months during radiotherapy, and then hydrolyzes and is eliminated.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.